10x Genomics, Inc.

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 11:49:54 2026-01-21 am EST			5-day change	1st Jan Change
22.14 ^USD	+0.43%		+6.21%	+36.24%

Jan. 12	10x Genomics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 08:15 AM
Jan. 12	Cancer Research Institute Launches Transformative Ai-Driven Immuno-Oncology Initiative Powered by 10X Genomics Technology	CI

10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 11/06/2025 at 04:05 pm EST

S&P Capital IQ

10X GENOMICS, INC.

+0.43%

10x Genomics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 149 million compared to USD 151.65 million a year ago. Net loss was USD 27.47 million compared to USD 35.75 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.3 a year ago.
For the nine months, revenue was USD 476.79 million compared to USD 445.76 million a year ago. Net loss was USD 27.29 million compared to USD 133.6 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 1.11 a year ago.

Latest news about 10x Genomics, Inc.

Jan. 12	10x Genomics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 08:15 AM
Jan. 12	Cancer Research Institute Launches Transformative Ai-Driven Immuno-Oncology Initiative Powered by 10X Genomics Technology	CI
Jan. 12	10X Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling	CI
Jan. 12	10X Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease	CI
Jan. 12	10x Genomics Unveils Collaborations in Oncology, Blood-Based Diagnostics	MT
Jan. 12	Cancer Research Institute launches transformative AI-driven immuno-oncology initiative powered by 10x Genomics technology	RE
Jan. 11	10X Genomics, Inc. Provides Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Jan. 07	CareDx, 10x Genomics Launch Platform to Study Transplant Rejection and Drug Response	MT
Jan. 07	CareDx, Inc. and 10x Genomics to Launch ImmuneScape - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response	CI
Dec. 11	Citigroup Downgrades 10x Genomics to Neutral From Buy, Price Target is $18	MT
Dec. 02	Morgan Stanley Downgrades 10x Genomics to Equalweight From Overweight, Lifts Price Target to $20 From $17	MT
Nov. 25	10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing	MT
Nov. 18	New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium	CI
Nov. 14	10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026	CI
Nov. 07	UBS Adjusts Price Target on 10x Genomics to $14 From $13, Maintains Neutral Rating	MT
Nov. 06	10x Genomics, Inc., Q3 2025 Earnings Call, Nov 06, 2025
Nov. 06	10X Genomics Q3 revenue beats expectations, net loss narrows	RE
Nov. 06	(TXG) 10x Genomics, Inc. Expects Q4 Revenue Range $154.0M - $158.0M	MT
Nov. 06	Earnings Flash (TXG) 10x Genomics, Inc. Reports Q3 Revenue $149.0M, vs. FactSet Est of $142.5M	MT
Nov. 06	10X Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2025	CI
Nov. 06	10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	10X Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research	CI
25-10-20	10x Genomics & Anthropic partner to make single cell & spatial analysis more accessible	RE
25-10-20	10x Genomics, Inc. and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences	CI
25-10-20	BofA Adjusts Price Target on 10x Genomics to $13 From $15	MT

Chart 10x Genomics, Inc.

Duration

Period

TXG: Dynamic Chart

Company Profile

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Employees

1,306

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 17 - Q4 2025 Earnings Release (Projected)

More about the company